Daraxonrasib Plus Chemo Halts or Shrinks Tumors in 90% in Trial

A daily pill combined with standard chemotherapy shrank or halted tumours in 90% of patients with newly diagnosed metastatic pancreatic cancer, with tumours becoming undetectable on scans in one in twelve participants, according to phase 1/2 trial results presented Friday at the EORTC-NCI-AACR Symposium in Barcelona.

The data, reported by The Guardian, show that adding the KRAS inhibitor daraxonrasib (marketed as Rasonque) to gemcitabine and nab-paclitaxel yielded a confirmed objective response rate of 60.7% in 61 treatment-naïve patients. Median progression-free survival reached 12.8 months — nearly double the historical 5.5 to 6.7 months seen with chemotherapy alone — while one-year overall survival stood at 76.6%, compared with the typical 40–45%.

Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center and the trial’s presenting investigator, described the depth of response as “the closest to cure” he has witnessed in advanced disease.

“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival.”

“Dr Park said during the plenary session in Barcelona.”

The findings mark the first time a RAS-targeted therapy has demonstrated such profound activity in the first-line metastatic setting. KRAS mutations, present in more than 90% of pancreatic ductal adenocarcinomas, have long been considered “undruggable” because the protein’s smooth surface lacked obvious binding pockets.

Daraxonrasib overcomes this by acting as a molecular glue: it binds the oncogenic RAS protein to cyclophilin A, locking RAS in an inactive conformation and blocking downstream signalling that drives uncontrolled tumour growth.

Targeted Pill Tested Upfront with Standard Chemo

  • A new first-line option: For the first time, a targeted pill is being tested upfront alongside standard chemo, not just after other treatments fail.
  • Unprecedented tumour shrinkage: Scans showed tumours disappearing completely in roughly 8% of patients — a rarity in metastatic pancreatic cancer.
  • More time, not yet a cure: Median time before cancer worsened was 12.8 months, but investigators do not yet know if this translates into long-term remission or overall survival benefit.

Revolution Medicines, the developer, announced the updated Phase 1/2 data on November 19, noting a disease control rate of 90.2% and a median duration of response of 11.1 months. The company confirmed the global Phase 3 RASolute-303 trial is underway, randomising patients to receive daraxonrasib plus chemotherapy versus chemotherapy alone — the critical comparison missing from the current single-arm study. Dr Park serves as principal investigator for RASolute-303.

Earlier Phase 2 data in previously treated patients, cited by The Telegraph, showed daraxonrasib monotherapy nearly doubled median overall survival to 13.2 months versus 6.7 months for standard care, moving some clinicians to tears. “I started crying in the clinic when I read the results,” Dr Rachna Shroff, a gastrointestinal cancer specialist at the University of Arizona, told The Telegraph.

The US Food and Drug Administration approved daraxonrasib in August 2026 for metastatic pancreatic adenocarcinoma that has progressed after at least one prior systemic therapy, based on that earlier cohort.

The European Medicines Agency and the UK’s Medicines and Healthcare products Regulatory Agency are reviewing applications for the same indication, while Cancer Research UK’s chief executive, Michelle Mitchell, called the first-line combination data “the biggest leap forward we’ve seen in decades for pancreatic cancer patients.”

Pancreatic cancer remains the deadliest common malignancy. In the UK, more than 11,500 people are diagnosed annually and over 10,200 die, according to Cancer Research UK. In the United States, the National Cancer Institute estimates tens of thousands of new cases and deaths in 2026. The five-year survival rate for metastatic disease hovers near 3%.

CT scans before and after treatment
Photo: BBC
Metric Daraxonrasib + Chemo (Phase 1/2, n=61) Historical Chemo Alone (First-Line)
Objective Response Rate 60.7% ~20–25%
Disease Control Rate 90.2% ~50–60%
Complete Response (Undetectable) 8.2% <1%
1-Year Overall Survival 76.6% 40–45%

The mechanism — targeting multiple RAS isoforms (G12D, G12V, G12R) rather than a single mutation — raises hope for broader application. RAS mutations drive roughly 25% of all solid tumours, including non-small cell lung cancer (KRAS G12C) and colorectal cancer.

Dr Sam Godfrey of Cancer Research UK told the BBC the drug has “found a way of drugging the undruggable” and expressed hope the strategy could extend to ovarian, lung, and other RAS-addicted cancers.

Safety data from the combination cohort showed manageable toxicity. The most common grade 3/4 adverse events were neutropenia, anaemia, and diarrhoea, consistent with the chemotherapy backbone. The prescribing information warns of gastrointestinal perforation risk and recommends dose interruption or reduction for severe diarrhoea.

Erin Agy, a 39-year-old mother of three from Trenton, Michigan, diagnosed with stage 4 disease in 2025, told WXYZ she has taken daraxonrasib for nearly two months; her tumour markers are trending down despite a difficult rash. “I got to see my daughter go to kindergarten, which I didn’t think I’d see. I turned 40, which was huge,” she said.

Who Should Not Take This Treatment and When to Seek Care

Daraxonrasib is contraindicated in patients with a history of severe hypersensitivity to the drug or its excipients. Clinicians should exercise caution in patients with active gastrointestinal ulceration or diverticulitis due to the perforation risk. Women of childbearing potential must use effective contraception during treatment and for one week after the final dose, as animal studies show embryo-fetal toxicity.

Patients experiencing new or worsening abdominal pain, fever, chills, or signs of bowel obstruction should seek immediate medical evaluation. Those with severe hepatic impairment (Child-Pugh C) have not been studied and should generally avoid the drug until safety data emerge.

Memorial Sloan Kettering Cancer Center traces its origins to the 1884 founding of New York Cancer Hospital, later renamed Memorial Hospital, and the 1945 creation of the adjacent Sloan-Kettering Institute for Cancer Research, funded by General Motors chairman Alfred P. Sloan and research director Charles F. Kettering.

The two entities formally coordinated operations in 1960 and merged in 1980. The center pioneered the first U.S. cancer research fellowship in 1927 and installed the world’s most powerful 900k-volt X-ray tube for cancer therapy in 1931.

The central question remains whether the profound early responses translate into a statistically significant overall survival advantage in the randomised Phase 3 trial. RASolute-303 is enrolling globally; top-line results are not expected before late 2027. Until then, daraxonrasib plus chemotherapy remains an investigational regimen for newly diagnosed metastatic patients outside clinical trials, though the FDA-approved monotherapy indication offers a validated option after first-line progression.

In a 61-patient trial, a daily pill called daraxonrasib plus chemotherapy stopped pancreatic… — Learnr

References

  • Park W, et al. Daraxonrasib plus Gemcitabine/Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma. Presented at EORTC-NCI-AACR Symposium, Barcelona, November 20, 2026. Abstract 8 LBA.
  • Revolution Medicines, Inc. Phase 1/2 RMC-GI-102 Updated Results Press Release. November 19, 2026.
  • US Food and Drug Administration. FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma. August 2026.
  • Cancer Research UK. Pancreatic Cancer Statistics. Accessed November 2026.
  • National Cancer Institute. SEER Cancer Stat Facts: Pancreatic Cancer. 2026 estimates.

Photo of author

Health Desk

Health Desk at Archyde.

Pokémon GO Unlocks 2026 Community Day Moves for 14 Evolutions Dec 12-13 36-Hour Window

Harriet Clark’s Novel ‘the Hill’ Explores Childhood Prison Visits